Vanguard Group Inc Akebia Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.37 Trillion
- Q1 2025
A detailed history of Vanguard Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 12,685,803 shares of AKBA stock, worth $38.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,685,803
Previous 10,884,200
16.55%
Holding current value
$38.4 Million
Previous $20.2 Million
20.31%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding AKBA
# of Institutions
157Shares Held
96.8MCall Options Held
98.6KPut Options Held
320K-
Black Rock Inc. New York, NY11.6MShares$35.3 Million0.0% of portfolio
-
State Street Corp Boston, MA6.81MShares$20.6 Million0.0% of portfolio
-
Satter Management Co., L.P.5.75MShares$17.4 Million20.26% of portfolio
-
Geode Capital Management, LLC Boston, MA5.03MShares$15.2 Million0.0% of portfolio
-
Great Point Partners LLC Greenwich, CT4.97MShares$15.1 Million5.9% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $557M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...